The EVACS (Evolocumab in Acute Coronary Syndrome) trial investigated the safety, feasibility, and efficacy of initiating the PCSK9 inhibitor evolocumab during hospitalization for acute coronary syndrome (ACS), specifically targeting patients with non-ST-elevation myocardial infarction (NSTEMI). This evidence concerns the gene PCSK9 and acute coronary syndrome.